Thrixen is a pioneering brand that specializes in the development of innovative technologies for biomarker detection and rapid assay generation. Founded by a team of international scientists from Singapore and the USA, Thrixen emerged as a spin-off from the prestigious Singapore-MIT Alliance in Research and Technology (SMART) in 2021. With extensive research and expertise, Thrixen has revolutionized the field of diagnostics by offering proprietary technologies that enable breakthrough rapid diagnostic platforms.

Their flagship product, the CoVIm System, is a state-of-the-art rapid point-of-care SARS-CoV-2 neutralizing antibody test. This unique test delivers accurate results within just 10 minutes, making it an invaluable tool in the fight against the global pandemic. Thrixen's dedication to innovation and precision has garnered recognition, as they feature prominently in various news outlets.

Their commitment to scaling diagnostics worldwide is reflected in their headquarters located at 9 Raffles Place, Republic Plaza, Singapore. To learn more about Thrixen's groundbreaking technologies and to get in touch, visit their website or contact them directly. Join Thrixen in shaping the future of diagnostics